Free public records show Artiva Biotherapeutics, Inc. in 2 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Artiva Biotherapeutics, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: SEC EDGAR, Company filings, CIK 1817241. Retrieved 13 Nov 2026.
2 active studies led by Artiva Biotherapeutics, Inc., of 4 in all
Source: ClinicalTrials.gov, Studies with Artiva Biotherapeutics, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1817241.
Studies Artiva Biotherapeutics, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Artiva Biotherapeutics, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Artiva Biotherapeutics, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Artiva Biotherapeutics, Inc. is in.
Stories on the topics Artiva Biotherapeutics, Inc. works in.
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Doctors' groups such as ACOG support public cord blood donation, but say routine private banking is not…
Read
Every vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
ReadSearch all reports for Artiva Biotherapeutics, Inc. All companies